The key elements of the BAF are:

- A description of each Principal (strategic) Risk, that forms the basis of the Trust's risk framework (with corresponding corporate and operational risks defined at a Trust-wide and service level)
- Risk ratings current (residual), tolerable and target levels
- Clear identification of primary strategic threats and opportunities that are considered likely to increase or reduce the Principal Risk, within which they are expected to materialise
- A statement of risk appetite for each threat and opportunity, to be defined by the Lead Committee on behalf of the Board (Averse = aim to avoid the risk entirely; Minimal = insistence on low risk options; Cautious = preference for low risk options; Open = prepared to accept a higher level of residual risk than usual, in pursuit of potential benefits)
- Key elements of the risk treatment strategy identified for each threat and opportunity, each assigned to an executive lead and individually rated by the lead committee for the level of assurance they can take that the strategy will be effective in treating the risk (see below for key)
- Sources of assurance incorporate the three lines of defence: (1) Management (those responsible for the area reported on); (2) Risk and compliance functions (internal but independent of the area reported on); and (3) Independent assurance (Internal audit and other external assurance providers)
- Clearly identified gaps in the primary control framework, with details of planned responses each assigned to a member of the Senior Leadership Team (SLT) with agreed timescales

Key to lead committee assurance ratings	Key to le	ead	committee	assurance	ratings:
---	-----------	-----	-----------	-----------	----------

- Green = Positive assurance: the Committee is satisfied that there is reliable evidence of the appropriateness of the current risk treatment strategy in addressing the threat or opportunity
  - no gaps in assurance or control AND current exposure risk rating = target
  - OR
  - gaps in control and assurance are being addressed
- Amber = Inconclusive assurance: the Committee is not satisfied that there is sufficient evidence to be able to make a judgement as to the appropriateness of the current risk treatment strategy
- Red = Negative assurance: the Committee is not satisfied that there is sufficient reliable evidence that the current risk treatment strategy is appropriate to the nature and/or scale of the threat or opportunity

This approach informs the agenda and regular management information received by the relevant lead committees, to enable them to make informed judgements as to the level of assurance that they can take and which can then be provided to the Board in relation to each Principal Risk and also to identify any further action required to improve the management of those risks.

Likelihood score and descriptor									
	Very unlikely 1	Unlikely 2	Possible 3	Somewhat likely 4	Very likely 5				
Frequency How often might/does it happen	This will probably never happen/recur	Do not expect it to happen/recur but it is possible it may do so	Might happen or recur occasionally or there are a significant number of near misses / incidents at a lower consequence level	Will probably happen/recur, but it is not necessarily a persisting issue/ circumstances	Will undoubtedly happen/recur, possibly frequently				
<b>Probability</b> Will it happen or not?	Less than 1 chance in 1,000 (< 0.1%)	Between 1 chance in 1,000 and 1 in 100 (0.1 - 1%)	Between 1 chance in 100 and 1 in 10 (1- 10%)	Between 1 chance in 10 and 1 in 2 (10 - 50%)	Greater than 1 chance in 2 (>50%)				

to the current exposure risk rating

This BAF includes the following Principal Risks (PRs) to the Trust's strategic priorities:

Reference	Principal risk	Lead director	Initial date of assessment	Last reviewed	Target risk score C x L	Previous risk score (at previous review/update) C x L	Current risk score C x L
PR1	Significant deterioration in standards of safety and care	Medical Director	01/04/2018	12/09/2022	4 x 2 = 8	4 x 4 = 16	4 x 4 = 16
PR2	Demand that overwhelms capacity	Chief Operating Officer	01/04/2018	12/09/2022	4 x 2 = 8	4 x 4 = 16	4 x 4 = 16
PR3	Critical shortage of workforce capacity and capability	Director of People	01/04/2018	25/10/2022	4 x 2 = 8	4 x 3 = 12	4 x <del>3<u>4</u> = <u>1216</u></del>
PR4	Failure to achieve the Trust's financial strategy	Chief Financial Officer	01/04/2018	25/10/2022	4 x 2 = 8	4 x 4 = 16	4 x 4 = 16
PR5	Inability to initiate and implement evidence-based improvement and innovation	Director of Culture and ImprovementChief Executive	17/03/2020	25/10/2022	3 x 2 = 6	3 x 3 = 9	3 x 3 = 9
PR6	Working more closely with local health and care partners does not fully deliver the required benefits	Director of Strategy and Partnerships	01/04/2020	11/10/2022	2 x 2 = 4	2 x 3 = 6	2 x 3 = 6
PR7	Major disruptive incident	Director of Corporate Affairs	01/04/2018	11/10/2022	4 x 1 = 4	4 x 3 = 12	4 x 3 = 12
PR8	Failure to deliver sustainable reductions in the Trust's impact on climate change	Chief Financial Officer	22/11/2021	11/10/2022	3 x 2 = 6	3 x 3 = 9	3 x 3 = 9



Principal risk (what could prevent us achieving this strategic objective)	Signific	ant deterioratio				•	he Trust resulting in s	ubstantial incidents		Stra	tegic objective	1. To pr			
Lead committee	Quality	,	Risk rating	Current exposure		Tolerable	Target	Risk type	Patient harm	20					
Lead director	Medica	ll Director	Consequence	4. High		4. High	4. High	Risk appetite	Minimal	15					
Initial date of assessment	01/04/	2018	Likelihood	4. Somewhat likel	ly	3. Possible	2. Unlikely			5					
Last reviewed	12/09/	2022	Risk rating	16. Significant		12. High	8. Medium			0		-22 -22			
Last changed	12/09/	2022									Oct-21 Nov-21 Dec-21 Jan-22	Feb-22 Mar-22 Apr-22			
A widespread loss of organisational focus patient safety and of of care leading to increased incidence avoidable harm, exp to 'Never Events', h than expected mort	<ul> <li>what might cause this to happen)</li> <li>(what controls/ systems &amp; processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)</li> <li>Clinical service structures, accountability &amp; qualities governance arrangements at Trust, division &amp; service levels including:         <ul> <li>Clinical service structures, accountability &amp; qualities governance arrangements at Trust, division &amp; service levels including:</li> <li>Monthly meeting of Patient Safety Committee (PSC) with work programme aligned to CQC registration regulations</li> <li>Nursing and Midwifery and AHP Business meeting</li> <li>Clinical policies, procedures, guidelines, pathways</li> </ul> </li> </ul>					s in control fic areas / issues a further work is red to manage the risk epted ite/tolerance level) of real time data ction	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?) Review of informatics function and development of informatics strategy SLT Lead: Chief Digital Information Officer Timescale: January 20	e Management: Lea Strategic Priority R Committee bi-anne Quality and Govern →Quality Committ reports include: 23 - DPR Report to - PSC assurance	rols/ systems which we rning from deaths I eport to Board; Div ually; Guardian of S nance Reporting Pa	-monthly					
patient satisfaction		<ul> <li>Clinical audit arrangemen</li> <li>Clinical staff training, reg</li> <li>Defined safe wards &amp; dep monitored b</li> <li>Ward assura programme</li> <li>Nursing &amp; M</li> <li>AHP Strateg</li> <li>Scoping and</li> <li>Internal Rev</li> <li>Getting it Rig dives, report</li> <li>CQC Bi-mont</li> <li>Operational the Incident</li> </ul>	recruitment, indu istration & re-valid e medical & nurse s partments (Nursing by Chief Nurse) ince/ metrics and a lidwifery Strategy y sign-off process fo iews against Extern ght First Time (GIR ts and action plans thly Engagement N	onitoring ction, mandatory lation staffing levels for all safeguards accreditation or incidents and Sis hal National Reports FT) localised deep Meetings gaps reporting into	and r gaps acros whicl the q	ical, nursing, AHP maternity staff in key areas ss the Trust, h may impact on quality and dard of care	Continued focus on recruitment and retention in significant impacted areas, including system wide oversight <b>SLT Lead:</b> Executive Director of People <b>Progress:</b> People, <u>Culture and</u> Improvement Strategy launched, and a numb of task and finish grou established <b>Timescale:</b> September 2022March 2023	<ul> <li>CYPP report to</li> <li>Medical Education</li> <li>Medicines Op</li> <li>Outputs from interincluding HSIB and</li> <li>Risk and complian</li> <li>Quality Account Report to PSC monitering</li> <li>Report to RC montering</li> <li>Independent assummation</li> <li>Screening Quality Account and</li> <li>Breast Cancering</li> <li>Gervical Screee</li> <li>External Accreditation</li> <li>Pathology (UK)</li> <li>Endoscopy Seine</li> <li>Medical Equip</li> </ul>	Annual Report to C o QC quarterly ation update report timisation Annual F nal reviews agains HQIP National and ce: Quality Dashbo port Qtrly to PSC a thly; CQC report to hly fance: CQC Engage thly Assurance Services New-born screeni Screening Services screening Services ning Services tion/Regulation and (AS)	t to QC Report t Extern l local F ard an nd QC QC bi- ment r assess ng hual as	to QC nal National Repo Reports d SOF to PSC Mor ; SI & Duty of Can monthly; Significa neeting reports to ments and report	nthly; dour ant Risk o Quality s of:			



pro	ovide outstanding care	
Apr-22	Tol lev	rrent risk level erable risk el get risk level
	Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
ly y		Positive No change since April 2020

Strategic threat (what might cause this to happen)	<b>Primary risk controls</b> (what controls/ systems & processes do we <b>already</b> have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
An outbreak of infectious disease (such as pandemic influenza; Coronavirus; norovirus; infections resistant to antibiotics) that forces closure of one or more areas of the hospital	<ul> <li>Infection prevention &amp; control (IPC) programme Policies/ Procedures; Staff training; Environmental cleaning audits</li> <li>PFI arrangements for cleaning services</li> <li>Root Cause Analysis and Root Cause Analysis Group</li> <li>Reports from Public Health England received and acted upon</li> <li>Infection control annual plan developed in line with the Hygiene Code</li> <li>Influenza and Covid vaccination programmes</li> <li>Public communications re: norovirus and infectious diseases</li> <li>Coronavirus identification and management process</li> <li>Infection Prevention and Control Board Assurance Framework</li> <li>Outbreak meeting including external representation, CCG, PHE, Regional IPC</li> <li>CQC IPC Key lines of enquiry engagement sessions</li> </ul>			Management: Divisional reports to IPC Committee (every 6 weeks); IPC Annual Report to QC and Board; Water Safety Group; IPC BAF report to PSC and QC <b>Risk and compliance:</b> IPC Committee report to PSC qtrly; SOF Performance Report to Board monthly; IPC Clinical audits in IPCC report to PSC qtrly; Regular IPC updates to ICT <u>; PLACE Assessment and Scores</u> <u>Estates Governance bi-monthly</u> <b>Independent assurance:</b> Internal audit plan; CQC Rating Good with Outstanding for Care May '20 <del>; PLACE Assessment and Scores Estates</del> <del>Governance bi-monthly; Public Health England UKHSA</del> attendance at IPC Committee; Independent Microbiologist scrutiny via IPC <u>Committee; Independent Microbiologist scrutiny via IPC</u> <u>Committee; Influenza vaccination cumulative number of staff</u> vaccinated; ICS vaccination governance report monthly; HSE visit (COVID-19 arrangements) Dec '21 – no concerns highlighted; IPC BAF Peer Review by Medway Trust; HSE External assessment and report; HSIB IPC assessment and report Nov '20	Business case to enhance oxygen capacity/flow has been delivered — BOC commencement date April 2022	Inconclusive Last changed April 2020



Principal risk (what could prevent us achieving this strategic objective)		PR 2: Demand that overwhelms capacity Demand for services that overwhelms capacity resulting in a deterioration in the quality, safety and effectiveness of patient care										
Lead committee	Quality	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient harm	20 -				
Lead director	Chief Operating Officer	Consequence	4. High	4. High	4. High	Risk appetite	Minimal	15 -				
Initial date of assessment	01/04/2018	Likelihood	4. Somewhat likely	4. Somewhat likely	2. Unlikely			10 - 5 -	••••	•••••		
Last reviewed	12/09/2022	Risk rating	16. Significant	16. Significant	8. Medium			0 -	21 21 21	22		
Last changed	12/09/2022								Oct-21 Nov-21 Dec-21 Jan-22	Feb-22 Mar-22		

Principal risk (what could prevent us achieving this strategic objective)	PR 2: Demand that ov Demand for services that ov care		ms capacity resulting in a deterioration in the quality, safety and effectiveness of pat							Strategic objective	1. To provid	de outstanding care				
Lead committee	Quality	Risk rating	Current exposure	Tolerabl	e	Target	Risk type	Patient ha	rm	20						
Lead director	Chief Operating Officer	Consequence	4. High	4. High		4. High	<b>Risk appetite</b>	Minimal		15		Curra	ent risk level			
Initial date of assessment	01/04/2018	Likelihood	4. Somewhat likely	4. Some	what likely	2. Unlike	ely	1				Tolerable risk				
Last reviewed	12/09/2022	Risk rating	16. Significant	16. Signi	ificant	um		0 0ct-21 Dec-21 Jan-22 Feb-22 Mar-22			Targe	et risk level				
Last changed	12/09/2022									Oct-21 Nov-21 Dec-21 Jan-22	Apr Mar Mav	unul Julu Sep				
Strategic threat (what might cause this to	t might cause this to happen) (what controls/ systems & processes do we <b>already</b> have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)				Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)			order to ( <u>Ev</u>	rder to (Evidence that the controls/ systems which we are			Gaps in assurance / actions to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating			
Growth in demand for caused by: • An ageing populati • A further Covid 19 admissions driven Omicron variant • Increased acuity le more admissions a longer length of sta	<ul> <li>Single streaming with NEMs</li> <li>Trust and System</li> <li>Cancer Improven</li> <li>Trust leadership</li> <li>ading to</li> <li>Patient pathway,</li> <li>Inter-professiona</li> <li>times such as dia</li> <li>Proactive system</li> <li>Together Alliance</li> <li>Patient Flow Imp</li> <li>SFH internal Win</li> <li>Referral manage secondary care</li> <li>MSK pathways</li> <li>COVID-19 Incider</li> <li>Some cancer series</li> <li>Elective Steering elective waiting t</li> <li>Accelerator Prog national Elective to help speed up</li> <li>Super Surge Plan</li> </ul>	process for ED & P escalation process nent plan of and attendance some of which are I standards across gnostics are compl leadership engage Delivery Board roving Patient Jour ter capacity plan & ment systems share at planning and gov vices maintained du to prioritise indivice Group now meetin imes meme – SFH has b Accelerator progra	at A&E Board i joint with NUH the Trust to ensure turna eted within 1 day ment from SFH into Bette ney Programme Mid Notts system capaci ed between primary and vernance process uring COVID-19 dual patients rg monthly to steer the re- eeen successful in being p mme attracting £2.5m of rvices	etings around er ity plan ecovery of <del>part of the</del> <del>f funding</del>				rep Ser Pla im do de 19 Ste we qu <b>Ris</b> to Ris Fra Re Inc to Bo Su Ma Fra	porting rvice Lin an to Bo provem cument mand a Recove eering C eekly; W arterly; sk and c Risk Co sk Repo arterly; sk and c Risk Co sk Repo port ind cident C TMT M ard Jun depend pport T ay '20; l	nent: Performance man arrangements betweer nes and Executive Team bard Nov '21; Cancer 62 nent plan to Board; Plan ts for 22/23 to identify and capacity gaps/bridg ery Plan to Board Sep '2 Group report to Executiv Vaiting list update to Board super Surge Plan to Board compliance: Divisional re mmittee bi-annually; Single rk to RC monthly; Single rk Integrated Monthly F cluding national ranking Control Team governand lar '20; Cancer services o '21 lent assurance: NHSI Im ream review of cancer p Performance Managem rk internal audit report	a Divisions, a; Winter -day aning clear es; COVID- 0; Elective ve Team ard bard Feb '22 risk reports gnificant e Oversight Performance as to Board; ce structure report to tensive processes ent		Positive Last changed December 2020			
Reductions in availab hospital bed capacity by increasing numbe MFFD (medically fit f discharge) patients re in hospital	v causedhospital bedsrs of• The provision ofortake forward thisemaining• Mitigation Plan to	a 'Discharge Cell' m work p reduce number o	of the number of MFFD p leeting with system partr f MSFT patients in hospit gned off by ICB August 2	ners to al beds <u>–</u>	Lack of cons achievemen Mid-Notts t for MSFT pa 22 – this is r associated v social care p (Pathway 1) related to h workforce s	nt of the hreshold atients of mainly with backages ) and is ome care	Business case for social ca expansion SLT Lead: <u>TBC</u> <u>Chief Opera</u> <u>Officer</u> Timescale: <u>TBC</u> <u>phased to</u> <u>2023</u> Virtual ward model of care funding plan to be conside Executive Team 27 <sup>th</sup> April SLT Lead: Chief Operating Timescale: April 2022	nting rep win Mi March pa Ris the the ee ered by	oorts in nter pla tigatior tients in <b>sk and o</b>	nent: Reporting into the to the system CEOs gro an presented to Board N n Plan to reduce numbe n hospital beds to Board compliance: Exception Per of MFFD into the Tru	up; Trust lov '21; or of MSFT d Dec '21 reporting on		Inconclusive New threat added January 2022			



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) ( <u>Evidence</u> that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
Operational failure of General Practice to cope with demand resulting in even higher demand for secondary care as the 'provider of last resort'	<ul> <li>Visibility on the CCG risk register/BAF entry relating to operational failure of General Practice</li> <li>Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development</li> <li>Weekly Executive meeting with the CCGs</li> <li>Weekly Mid Notts Network Calls</li> </ul>			<b>Management:</b> Routine mechanism for sharing of CCG and SFH risk registers – particularly with regard to risks for primary care staffing and demand		Inconclusive No change since April 2020
Drop in operational performance of neighbouring providers that creates a shift in the flow of patients and referrals to SFH	<ul> <li>Engagement in Integrated Care System (ICS), and assuming a leading role in Integrated Care Provider development</li> <li>Horizon scanning with neighbour organisations via meetings between relevant Executive Directors</li> <li>Weekly management meeting with the Service Director from Notts HC</li> <li>Bilateral work – Strategic Partnership forum</li> </ul>			<b>Risk and compliance:</b> Divisional NUH/SFH strategic partnership forum minutes and action log; NUH service support to SFH paper to Executive Team	Lack of control over the flow of patients from the surrounding area	Inconclusive No change since April 2020



Principal risk (what could prevent		-		pacity and cap	-	<b>ity</b> on of staff experience	morolo and w	all being which can		Strategic objective	3. To m	aximise the poter	atial of our wo	orkforce
us achieving this strategic objective)	have an adverse	· · ·		esuiting in a deter	Ioratio	on of stall experience	e, morale and w	en-being which can		Strategie objective	5.1011			interes in the second sec
Lead committee	People, Culture Improvement		Risk rating	Current exposu	re	Tolerable	Target	Risk type	Services	20				
Lead director	Director of Peop	le	Consequence	4. High		4. High	4. High	Risk appetite	Cautious					nt risk level
Initial date of assessment	01/04/2018		Likelihood	3. Possible 4. Somewhat like	<u>ely</u>	4. Somewhat likely	2. Unlikely		10 5			Tolerable risk		
Last reviewed	25/10/2022		Risk rating	12. High 16. Significant		16. Significant	8. Medium	8. Medium		0 Nov-21 Jan-22 Mar-22 Apr-22		n-22 g-22 p-22 tt-22	t risk level	
Last changed	25/10/2022									De De Za	A Z	n n N N		
Strategic threat (what might cause this			ems & processes do we jing the risk and reducir		(Specif further the risl	s in control fic areas / issues where or work is required to manage the to accepted appetite/ nce level)	(are further cont	<b>prove control</b> trols possible in order to sure within tolerable	Sources of assur (Evidence that the c reliance on are effect	controls/ systems which we are p	blacing	Gaps in assurance address gaps and relating to COVII	dissues	Assurance rating
relating to the wor	tic changes cant impact of nd/or unforeseen d shifting cultural rs, combined with tet factors (such as y and increased nental health issues rking environment, workforce gaps in	<ul> <li>People and In</li> <li>Culture and Ir</li> <li>Medical and N</li> <li>Activity, Work</li> <li>2-year workfor</li> <li>Planning Groupiob planning;</li> <li>capacity plans</li> <li>Vacancy manage and processes</li> <li>TRAC system for and procedure</li> <li>Defined safe rewards and depoperating Processes with</li> <li>Education par</li> <li>Director of Peculture Board</li> <li>Workforce plate</li> <li>Communication rules on pensity</li> </ul>	mprovement Cabin Nursing task force (force and Financia prce plan supported up and review proc workforce modellin s) agement and recru for recruitment; e- es used to plan sta medical & nurse sta partments / Safe S pocedure affing approval and h defined authorisa cruerships cople attendance a	et Il plan d by Workforce esses (consultant ng; winter itment systems Rostering systems ff utilisation affing levels for all taffing Standard d recruitment ation levels t People and work stream ng HMRC taxation	Medi mate areas which qualit Lack o the sy recru creat not m	nce level) ical, nursing, AHP and ernity staff gaps in key is across the Trust, h may impact on the ty and standard of care of consistency across ystem with regard to uitment and retention, ting competition and naximising ortunities	Improvement SLT Lead: Dire Timescale: M Visibility arou contributions the People ar development SLT Lead: Dire Timescale: O Involvement People Office SLT Lead: Dire	and Sherwood's to leading aspects of nd Culture across the system ector of People ctober 2022Complete in the recruitment ne system Chief	to Board; Nursin monthly staffing Workforce and G Quarterly Assura and Culture & In Improvement Co Retention repor Plan to PCI Com Relations Quarte Culture and Imp updates to PCI C Development St Committee Jun <i>G</i> <b>Risk and compli</b> risk report Mont report Risk Com Indicators (Mon (monthly); Guar Board quarterly <b>Independent as</b> NHSI use of reso Checks internal assurance; HSJ A	ance: Risk Committee sign thly; HR & Workforce plan mittee; SOF – Workforce thly); Bank and agency rep dian of safe working repo	P six rly; Inclusion Iture and cforce People, ople Plan adership to PCI nificant ning port rt to CQC; ment nificant he Year	Staff mental heal result of psycholo Potential impact changes to the p arrangements an <u>Explore the imple</u> payment via mul assignments to re tax liabilities <u>SLT Lead: Directo</u> <u>Timescale: Nove</u>	of pending ensions d NI rules <u>ementation of</u> <u>tiple</u> educe pension	Positive Last changed June 2022
	<ul> <li>advice</li> <li>Pensions restructuring payment introduce</li> <li>Risk assessments for at-risk staff groups</li> <li>Refined and expanded Health and Wellber support system</li> <li>Operational grip on workforce gaps report the Incident Control Team</li> <li>Nursing and Midwifery Workforce Transformation Cabinet</li> <li>Medical Workforce Transformation Cabinet</li> <li>Strategic People Plan</li> </ul>		groups nd Wellbeing aps reporting into ce Transformation						ommittee quarterly; Peop and Improvement Commi					




Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) ( <u>Evidence</u> that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
A significant loss of workforce productivity arising from a short- term reduction in staff availability or a reduction in effort above and beyond contractual requirements amongst a substantial proportion of the workforce and/or loss of experienced colleagues from the service, or caused by other factors such as poor job satisfaction, lack of opportunities for personal development, on-going pay restraint, workforce fatigue or wellbeing issues, or failure to achieve consistent values and behaviours in line with desired culture This could also lead to lack of engagement with patients, resulting in failure to address patient empowerment and self-help and failure to work across the system to enable personalised patient centred care	<ul> <li>People Culture and Improvement Strategy</li> <li>People and Inclusion Cabinet</li> <li>Culture and Improvement Cabinet</li> <li>Chief Executive's blog / Staff Communication bulletin</li> <li>Engagement events with Staff Networks (BAME, LGBT, WAND, Time to Change)</li> <li>Schwartz rounds</li> <li>Learning from COVID</li> <li>Staff morale identified as 'profile risk' in Divisional risk registers</li> <li>Star of the month / milestone events</li> <li>Divisional action plans from staff survey</li> <li>Policies (inc. staff development; appraisal process; sickness and relationships at work policy)</li> <li>Just and restorative culture</li> <li>Influenza vaccination programme</li> <li>COVID-19 vaccination programme</li> <li>Staff counselling / Occ Health support</li> <li>Enhanced equality, diversity and inclusion focus on workforce demographics</li> <li>Freedom to Speak Up Guardian and champion networks</li> <li>Emergency Planning, Resilience &amp; Response (EPRR) arrangements for temporary loss of essential staffing (including industrial action and extreme weather event)</li> <li>Combined violence and aggression campaign across system partners</li> <li>Anti-racism Strategy</li> <li>Industrial action group developing preparedness for the Trust and system</li> </ul>	Inequalities in staff inclusivity and wellbeing across protected characteristics groups	Deliver the People, Culture and Improvement Strategy – Year 1 SLT Lead: Director of People Timescale: March 2023	Management: Staff Survey Action Plan to Board May '21; Staff Survey Annual Report to Board Jun '21; Equality and Diversity Annual Report Jun '22; WRES and WDES report to Board Jun '21; Quarterly Assurance reports on People & Inclusion and Culture & Improvement to People Culture and Improvement Committee; Winter Wellness Campaign report to Board Oct '21; People Plan updates to People, Culture and Improvement Committee quarterly <b>Risk and compliance:</b> EPRR Report (bi-annually); Freedom to speak up self-review Board Aug '21; Freedom to Speak Up Guardian report quarterly; Guardian of Safe Working report to Board quarterly; Significant Risk Report to RC monthly; Gender Pay Gap report to Board Apr '21; Assurance Report to People, Culture and Improvement Committee quarterly; People Plan to People, Culture and Improvement Committee Apr'21; Anti-Racism Strategy to Board Mar '22; Mental Health Strategy to PCI Committee Jun '22 Independent assurance: National Staff Survey Mar '21; SFFT/Pulse surveys (Quarterly); Well-led report CQC; Well-led Review report to Board Apr '22; NHS People Plan – Focus on Equality, Diversity and Inclusion internal audit report Jun '22	Potential impact of cost of living issues on staff morale and wellbeing Expected increase in staff sickness and isolation levels due to COVID-19 and influenza Potential industrial action up to and including strike action from all NHS unions, affecting all system partners Finalise and implement the industrial action plan SLT Lead: Director of People Timescale: November 2022	Positive Inconclusive Last changed June 2022 October 2022



Principal risk (what could prevent us achieving this strategic objective)	<b>PR 4: Failure to achiev</b> Failure to achieve agreed tra			Strat	tegic objective	5: T				
Lead committee	Finance	Risk rating	Current exposure	Tolerable	Target	Risk type	Regulatory action	20 ·		
Lead director	Chief Financial Officer	Consequence	4. High	4. High	4. High	Risk appetite	Cautious	15 ·		
Initial date of assessment	01/04/2018	Likelihood	4. Somewhat likely	3. Possible	2. Unlikely			10 · 5 ·	•••••	••••
Last reviewed	25/10/2022	Risk rating	16. Significant	12. High	8. Medium			0 -		0 7
Last changed	25/10/2022								Nov-21 Dec-21 Jan-22 Feb-22	Mar-z Apr-2

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we <b>already</b> have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps	Assurance rating
A reduction in funding or change in financial trajectory or unexpected event resulting in an increased Financial Improvement Plan (FIP) requirement to reduce the scale of the financial deficit, without having an adverse impact on quality and safety	<ul> <li>5 year long term financial model</li> <li>Working capital support through agreed loan arrangements</li> <li>Annual financial plan and budgets, based on available resources and stretching financial improvement targets.</li> <li>Transformation and Efficiency Cabinet, FIP planning processes and PMO coordination of delivery</li> <li>Delivery of budget holder training workshops and enhancements to financial reporting</li> <li>Close working with ICB partners to identify system-wide planning, transformation and cost reductions</li> <li>Executive oversight of commitments</li> <li>COVID-19 related funding application process in place at Trust level</li> <li>Development of a three-year Transformation and Efficiency Programme covering 2022-25</li> <li>Forecast sensitivity analysis and underlying financial position reported to Finance Committee</li> <li>Capital Oversight Group</li> </ul>	Medium/Long Term Financial Strategy was developed pre- pandemic and does not reflect the current financial framework <u>Revenue business case</u> process may not adequately represent the longer-term priorities and potential consequences of future years	Financial strategy for 3-5 years to be developed at a Trust and Integrated Care Board level. SLT Lead: Chief Financial Officer Timescale: January 2023 <u>Review and implement enhanced business case</u> <u>process for 2023/24 planning and in-year</u> <u>prioritisation</u> <u>SLT Lead: Chief Financial Officer</u> <u>Timescale: January 2023</u>	Management: CFO's Financial Reports and Transformation & Efficiency Summary (Monthly); Quarterly Strategic Priority Report to Board; ICS finance report to Finance Committee (monthly); Capital Oversight Group; Divisional Performance Reviews (monthly); Divisional risk reports to Risk Committee bi-annually; Transformation & Efficiency Cabinet updates to Executive Team <b>Risk and compliance:</b> Risk Committee significant risk report Monthly <b>Independent assurance</b> : Deloitte audit of COVID-19 expenditure; <u>External</u> <u>Audit Year-end Report 2021/22</u> Internal Audit reports: - Key Financial Systems - Asset Register Jan '22 - Integrity of the General Ledger and Financial Reporting Dec '21 - Financial Reporting Arrangements Nov 21	Off trajectory to achieve <u>FIP target</u> <u>Reprioritisation to</u> <u>achieve FIP recovery plan</u> <u>SLT Lead: Chief Financial</u> <u>Officer</u> <u>Timescale: November</u> <u>2022</u>	Positive Last changed July 2022
ICB system deficit results in a negative financial impact to the Trust	<ul> <li>Full participation in ICB planning</li> <li>SFH plan consistency with ICB and partner plans</li> <li>ICB DoFs Group</li> <li>ICB Operational Finance Directors Group</li> <li>ICB Financial Framework</li> </ul>	ICB Medium/Long Term Financial Strategy to be developed	Financial strategy for 3-5 years to be developed at a Trust and Integrated Care Board level <b>SLT Lead</b> : Chief Financial Officer <b>Timescale:</b> TBC (dependant on NHSE/I and ICB Guidance)	<b>Risk and compliance:</b> ICS financial reports to Finance Committee; ICS Board updates to SFH Trust Board		Positive Last changed July 2022






Principal risk (what could prevent us achieving this strategic objective)		Inability to initiate and implement evidence-based improvement and innovation support, capability and agility to optimise strategic and operational opportunities to improve patient care							egic objective	4: To (
Lead committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Target	Risk type	Reputation	10 -		
Lead director	Director of Culture & ImprovementChief Executive	Consequence	3. Moderate	3. Moderate	3. Moderate	Risk appetite	Cautious	8 - 6 -		•••••
Initial date of assessment	17/03/2020	Likelihood	3. Possible	3. Possible	2. Unlikely			4 -		
Last reviewed	25/10/2022	Risk rating	9. Medium	9. Medium	6. Low			0 -	21 -21 -22 -22	22
Last changed	25/10/2022								I I	Mar-2 Apr-2

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) ( <u>Evidence</u> that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Lack of understanding and agility resulting in reduced efficiency and effectiveness around how we provide care for patients	<ul> <li>Digital Strategy</li> <li>People, Culture &amp; Improvement Strategy</li> <li>Quality Strategy</li> <li>People, Culture &amp; Improvement Committee</li> <li>Leadership development programmes</li> <li>Talent management map</li> <li>Programme Management Office</li> <li>Culture &amp; Improvement Cabinet</li> <li>Transformation Cabinet</li> <li>Ideas generator platform</li> </ul>		Establishment of an Innovation Hub <b>SLT Lead:</b> Director of Culture and Improvement <b>Timescale:</b> December 2022 <b>Progress:</b> Successful bid for £20k from the Health Foundation to support development of an organisational level Innovation Hub, and a Provider Collaborative Hub between SFH, NUH and NHCT	Management: Monthly Transformation and Efficiency report to FC; Clinical Audit & Improvement report to Advancing Quality Group quarterly; Culture & Improvement Assurance Report to PC&IC bi-monthly <b>Risk and compliance:</b> SOF Culture and Improvement indicators; SFH Trust Priorities to Board quarterly <b>Independent assurance:</b> Internal Audit of FIP/ QIPP processes Sep '21; 360 assessment in relation to Clinical Effectiveness - report May 2022	Delays in training, planned improvement and innovation programmes due to COVID-19 Lack of capacity for colleagues to engage with improvement <u>Consider ways to provide the</u> capacity to progress improvement activity <u>SLT Lead: Chief Executive</u> <u>Timescale: December 2022</u>	Positive Inconclusive No change since April 2020Last changed October 2022






Principal risk (what could prevent us achieving this strategic objective)	required benefits Influencing the wider determinat	uencing the wider determinants of health and improving our collective financial position requires close partnership rking. This may be difficult because of differences in governance, objectives and appetite for and ability to change								2: To pr
Lead committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services			
Lead director	Director of Strategy and Partnerships	Consequence	2. Low	2. Low	2. Low	Risk appetite	Cautious	8 - 6 -		
Initial date of assessment	01/04/2020	Likelihood	3. Possible	4. Somewhat likely	2. Unlikely			4 - 2 -		•••••
Last reviewed	11/10/2022	Risk rating	6. Low	8. Medium	4. Low			0 +	-21 -22 -22	-22
Last changed	11/10/2022								Nov-22 Dec-27 Jan-27 Feb-27	Mar-22 Apr-22

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we <b>already</b> have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Conflicting priorities, financial pressures (system financial plan misalignment) and/or ineffective governance resulting in a breakdown of relationships amongst ICS and ICP partners and an inability to influence further integration of services across acute, mental, primary and social care	<ul> <li>Mid-Nottinghamshire Integrated Care Partnership Board</li> <li>Mid-Nottinghamshire ICP Executive formed May 2020</li> <li>Mid-Nottinghamshire ICP breakthrough objectives signed off July 2020</li> <li>Nottingham and Nottinghamshire Integrated Care System Board</li> <li>Continued engagement with ICP and ICS planning and governance arrangements</li> <li>Quarterly ICS performance review with NHSEI</li> <li>Joint development of plans at ICS level</li> <li>Finance Directors Group</li> <li>ICS Planning Group</li> <li>Alignment of Trust, ICS and ICP plans</li> <li>Full alignment of organisational priorities with system planning for 2022/23</li> <li>Independent chair for ICP</li> <li>ICS Transition and Risk Committee</li> <li>Approved implementation plan for establishing system risk arrangements</li> <li>ICS Provider Collaborative development</li> <li>ICS System Oversight Group</li> <li>Engagement with the establishment of the formal ICB and place- based partnership</li> <li>SFH Chief Executive is a member of the ICB as a partner member representing hospital and urgent &amp; emergency care services (both formally established on 1<sup>st</sup> July 2022)</li> </ul>	Suboptimal system oversight and arrangements for discharge of complex patients	Consideration by ICS Chief Executives Group of sustainable architecture to enable effective and timely discharge of MFFD patients. Provider collaborative considering taking ownership SLT Lead: Chief Executive Officer Timescale: TBCComplete	Management: Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Nottingham and Nottinghamshire ICS Leadership Board Summary Briefing to Board; Planning Update to Board <b>Risk and compliance:</b> Significant Risk Report to RC monthly <b>Independent assurance</b> : 360 Assurance review of SFH readiness to play a full part in the ICS – Significant Assurance		Positive Last changed May 2022
Clinical service strategies and/or commissioning intentions that do not sufficiently anticipate evolving healthcare needs of the local population and/or reduce health inequalities	<ul> <li>Continued engagement with commissioners and ICS developments in clinical service strategies focused on prevention</li> <li>Partnership working at a more local level, including active participation in the mid-Nottinghamshire ICP</li> <li>ICS Clinical Services Strategy now complete</li> <li>ICS Health and Equality Strategy</li> <li>ICS Clinical Services workstreams are well established across elective and urgent care and SFH is represented and involved appropriately</li> </ul>	The needs of the population and the statutory obligations of each individual organisation will not be met until the ICS Clinical Services Strategy is implemented	Implement the ICS Clinical Services StrategyRefreshed ICS Clinical Services Strategy led by the ICB Medical Director SLT Lead: Medical Director Timescale: TBCSeptember 2023 Progress: ICB Medical Director appointed - initial focus to formulate ICB Clinical Strategy building on previous work around ICS Clinical Services Strategy	Management: Mid-Notts ICP Objectives Update to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Planning Update to Board Independent assurance: none currently in place		Inconclusive Positive Last changed May October 2022





1

Principal risk (what could prevent us achieving this strategic objective)	A majo	Major disruptive in or incident resulting in ten ust, which also impacts sig	nporary hospital cl	•		the co	ontinuity of co	ore services ac	cross		Stra	ategic	c objective	1: To p
Lead committee	Risk		Risk rating	Current exposure	Tolerable	Tar	get	Risk type		Services	15	Τ		
Lead director	Directo	or of Corporate Affairs	Consequence	4. High	4. High	4.⊦	ligh	Risk appetit	e	Cautious	10			
Initial date of assessment	01/04/	2018	Likelihood	3. Possible	3. Possible	1. \	/ery unlikely				5			• • • • • • • •
Last reviewed	11/10/	2022	Risk rating	12. High	12. High	4. L	.ow	_			0	Nov-21	Dec-21 Jan-22 Feb-22	Apr-22
Last changed	09/08/	2022										No	La Ja	A A
Strategic threat (what might cause this t		Primary risk controls (what controls/ systems & proce managing the risk and reducing t			Gaps in contro (are further controls in order to reduce ris exposure within toler range?)	oossible k	Plans to in control (are further con order to reduce within tolerable	trols possible in risk exposure		<b>s of assurance (ar e</b> that the controls/ sy fective)			e are placing relia	ance ga
Shut down of the IT network due to a la scale cyber-attack of system failure that severely limits the availability of esser information for a prolonged period	arge- or	<ul> <li>Information Governan NHIS Cyber Security St</li> <li>Cyber Security Progran Group and work plan</li> <li>Cyber news – circulate</li> <li>High Severity Alerts iss</li> <li>Network accounts che disabled after 80 days</li> <li>Major incident plan in</li> <li>Periodic phishing exerce</li> <li>Spam and malware em</li> <li>Periodic cyber-attack e Trust's EPRR lead</li> </ul>	rategy nme Board & Cyber d to all NHIS partner ued by NHS Digital cked after 50 days o if not used place cises carried out by 3 hail notifications circ exercises carried out	Security Project rs f inactivity – 360 Assurance ulated					submis complia Report Securit' Board r quarter Cyber S levels c <b>Risk an</b> <b>Indepe</b> Securit' Assuran 19 on t '21- Sig Govern 360 Ass audit <del>N</del> IT Healt assurar	ement: Data Secu sion to Board Apr ance <u>compliant on</u> to Cyber Security y Assurance Highl monthly; NHIS rep rly; IG Bi-annual re Security report to of attack due to UI d compliance: ndent assurance: y Management Ce nce Cyber Security he NHS Dec '20; C surficant Assuranc ance and Interfac surance Data Secu tay '21Jul '22 – su thcheck – 2 of 9 e nce); Cyber Essent	21Jul 108/1 Board ight Re port to eport to eport to Risk Co kraine ISO 27 ertifica y Surve CG Cyl e; 360 re audit urity an bstant lement cials Plu	<u>'22</u> - <u>4</u> mont eport t Risk C o Risk ommit 7001 In tion; T ey - Th ber Se Assura t – lim d Prot ial <u>mo</u> ts faile us accu	ements; Hygie chly; Cyber to Cyber Secu committee Committee; ctee – increase nformation FIAN / 360 e impact of C curity Report ance NHIS nited assurance tection Toolk oderate assura ed (negative reditation Jan	ene rity ed ovid- Mar e; it ance;
A critical infrastruct failure caused by an interruption to the of one or more utili (electricity, gas, wa uncontrolled fire, fl other climate chang impact, security inc failure of the built environment that r a significant propor the estate inaccess unserviceable, disru services for a prolo period	n supply ities ter), an lood or ge cident or enders rtion of ible or upting	<ul> <li>Premises Assurance M</li> <li>Estates Strategy 2015-</li> <li>PFI Contract and Estate Partners</li> <li>Fire Safety Strategy</li> <li>NHS Supply Chain resil</li> <li>Emergency Preparedne arrangements at regio</li> <li>Operational strategies incident (e.g. industria disease; power failure; CBRNe)</li> <li>Gold, Silver, Bronze co</li> <li>Business Continuity, Ei</li> <li>Resilience Assurance C</li> <li>Independent Authorisi</li> <li>Major incident plan in</li> </ul>	2025 es Governance arrar ience planning ess, Resilience & Res nal, Trust, division a & plans for specific l action; fuel shortag severe winter weat mmand structure fo mergency Planning & committee (RAC) ove ng Engineer (Water)	sponse (EPRR) nd service levels types of major ge; pandemic her; evacuation; r major incidents & security policies ersight of EPRR					monthl Report; Commi QC Mai <b>Risk an</b> to Risk <b>Indepe</b> RC Dec (Oct'21 (WSP) t – hard Recerti	ement: Central N y performance re ; Water Safety Up ttee Jul '20; Patie rch '21; Hard and d compliance: Me Committee ndent assurance: '18; EPRR Core st .) – Substantial As to Joint Liaison Co FM independent a fication Mar '21; I Assessment Repo	port; F date R nt Safe soft FN onthly Premi andarc suranc mmitte audit; P British	ire Sat eport ety Cor A assu Signifi ses As ds com ee; Wa ee Oct MEMD Stand	fety Annual to Risk ncerns report irance report icant Risk Rep ssurance Mod npliance ratin ter Safety rep t '19; WSP rep D ISO 9001:20	to s port el to g port port 15



provide outstanding care	
Tolera	it risk level ble risk level risk level
Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
	Positive No change since April 2020
	Positive No change since April 2020

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
A critical supply chain failure that severely restricts the availability of essential goods, medicines or services for a prolonged period	<ul> <li>NHS Supply Chain resilience planning Business Continuity Management System &amp; Core standards</li> <li>CAS alert system – Disruption in supply alerts</li> <li>Major incident plan in place</li> <li>PPE Strategy</li> <li>COVID-19 Pandemic Surge Plan</li> <li>Procurement Influenza Pandemic Business Continuity Plan</li> <li>Interim provision for transmission of personal data to the United Kingdom clause within the EU Exit agreement</li> </ul>			Management: Procurement Annual Report to Audit & Assurance Committee; Oxygen Supply Assurance report to Incident Control Team Apr '20; COVID-19 Governance Assurance Report to Board May '20 Risk and compliance: Independent assurance: <u>2020/212021/22</u> Counter Fraud, Bribery and Corruption Annual Report; 360 Assurance Procurement Review Apr '21 – Significant Assurance; 360 Assurance internal audit of contract management – limited assurance		Positive No change since April 2020



Principal risk (what could prevent us achieving this strategic objective)	The vision to further embed sust	Current							itegic objective	2: To pro
Lead committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Reputation / regulatory action	10		
Lead director	Chief Financial Officer	Consequence	3. Moderate	3. Moderate	3. Moderate	Risk appetite	Cautious	6		•••••
Initial date of assessment	22/11/2021	Likelihood	3. Possible	3. Possible	2. Unlikely			4 · 2 ·		
Last reviewed	11/10/2022	Risk rating	9. Medium	9. Medium	6. Low			0 ·	\ \	· · ·
Last changed	13/09/2022							4	Decy Bury tepy way	APT NRAY

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Failure to take all the actions required to embed sustainability and reduce the impact of climate change on our community	<ul> <li>Estates &amp; Facilities Department oversee the plan and education on climate change impacts</li> <li>Green Plan 2021-2026</li> <li>Climate Action Project Group</li> <li>Engagement and awareness campaigns (internal/external stakeholders)</li> <li>Estates Strategy</li> <li>Digital Strategy</li> <li>Capital Planning sustainability impact assessments</li> <li>Environmental Sustainability Impact Assessments built into the Project Implementation Documentation process</li> <li>Engagement with the wider NHS sustainability sector for best practice, guidance and support</li> <li>Process in place for gathering and reporting statistical data</li> </ul>	Education of Board and staff at all levels <u>Dedicated capacity to</u> <u>implement ideas for</u> <u>change</u>	Training of the Board, decision makers and all staff at an appropriate level to increase awareness and understanding of sustainable healthcare Lead: Associate Director of Estates and Facilities Timescale: December 2022 Review of existing approaches and capacity to act on ideas to improve the Trust's impact on climate change. Lead: Chief Financial Officer Timescale: October 2022 Proposal to ICB partners for collaborative approach and resource. Lead: Chief Financial Officer Timescale: October 2022	Management: Risk and compliance: Green Plan to Board Apr '21 Sustainability Report included in the Trust Annual Report Independent assurance: ERIC returns and benchmarking feedback	Reporting to Transformation and Efficiency Cabinet not yet defined Governance structure for reporting on progress to be confirmed Agree reporting structure Lead: Associate Director of Estates and FacilitiesChief Financial Officer Timescale: July October 2022	Inconclusive New risk added November 2021



